Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1

6)(q25;p23) After Treatment for High-risk Neuroblastoma

Whittle, Sarah B. MD*; Punia, Jyotinder N. MD; López-Terrada, Dolores MD, PhD*,†; Gaikwad, Amos PhD*; Hampton, Oliver A. PhD; Heczey, Andras MD*

Journal of Pediatric Hematology/Oncology: November 2017 - Volume 39 - Issue 8 - p e486–e488
doi: 10.1097/MPH.0000000000000956
Online Articles: Clinical and Laboratory Observations
Buy

Neuroblastoma is the most common extracranial malignancy of childhood. Patients with high-risk disease receive multimodal treatment including chemotherapy combinations containing alkylating agents and topoisomerase inhibitors with potential for inducing therapy-related malignancy later in life. Most commonly, cytogenetic changes of pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia involve chromosome 5 or 7. Here we report a novel case of therapy-related myelodysplastic syndrome/acute myeloid leukemia 30 months after treatment for high-risk neuroblastoma with biphenotypic cell surface markers and a not yet described translocation t(1;6)(q25;p23).

*Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine/Texas Children’s Hospital

Department of Pathology and Immunology

Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX

The authors declare no conflict of interest.

Reprints: Sarah B. Whittle, MD, 6701 Fannin Street, Suite 1580.13, Houston, TX 77030 (e-mail: sbwhittl@txch.org).

Received January 14, 2017

Accepted July 12, 2017

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.